IMU (ASX) Ann: Imugene Capital Raising Presentation

Originally posted by Taureanbull: ↑

Jov88, Another good post. However the common myth here is that the dilution is 20%. If we break down the numbers I get a Dilution of 6.5%. At present there are roughly 6.4bn shares on issue. The Instos and Directors get $35m worth of share at .084 cents. That’s 6.5%. The SPP give most shareholders especially small shareholders the opportunity to buy $30,000 at ~.o84. So roughly another 6.5%. Is that DILUTION or is it topping up capital as a business owner/ part business owner to buy in new assets ? I would definitely say this is increasing a shareholders investment in an increasingly bigger and better company.

So today any shareholder can buy shares at .079. The new IMUOE are convertible before Aug 2026 at .115 cents. Or shareholders can buy shares right now on the open market for .079 cents. I don’t see any dilution or massive discount there. In fact that’s probably fairly priced.

For all the blood curdling screams and plans of revenge coming from the keyboard warriors and armchair experts out there, who have absolutely NO EXPERIENCE in running a start-up , running a Biotech Company. Little to NO experience investing let alone investing in the most difficult sector the stock market , they should take the time to consider what LC has said in the announcements.

This acquisition, is an ORPHAN DRUG which comes with the best DATA PACKAGE of any Allogenic CD19 Directed CarT therapy in the world. It’s passed it’s safety trial with 84 patients. With a very high ORR of 84%. all at the cost of a 6.5% dilution

This amazing deal comes with the highly specialised factory and team to produce the Therapy. This is a requirement that satisfies the FDA requirements to get Marketing Approval. That’s a big item ticked off.

Now IMU owns the whole game. The biggest game in town ONCOLOGY . That’s Solid tumors and liquid tumors. All in one UNIVERSAL VACCINE. Not only that, there’s more. In JUNE a meeting was held with the FDA about progressing this drug to a Registrational trial starting in 2024. What we don’t know at this point , is who was there. Was LC or Dr Jakob DuPont invited along to this meeting? I suspect they were.

What is our next move ? We probably should expect a variation to our Oncarlytics FDA IND to include an arm that uses our new CarT. Now that we have both CF33 Oncovirus and CarT therapies that have passed safety trials we are ready to head for Breakthrough Approval for our Universal Vaccine.

This is so breathtaking the scope and scale! What IMUGENE has achieved in les than 4 years is staggering, if you understand Biotech. Yuman FONG definitely thinks the achievements o PH and LC are amazing, he keeps telling us this. Like dog years , Biotech years are about 5 human years to One biotech year. This will get IMU a spot in the Guinness Book of records. And CEO LC will win the Biotech CEO of the century with this achievement.

For new investors to Biotech, there is a stage in the lifecycle of. Biotech that’s called the “Valley of Death”. All start up Bios must pass through the valley of death before success. If you have read Steini’s post ripping into your Chairman Paul Hopper for the non-performance of his other ASX listed companies CHM and RAD, you will see the effects of travelling thru the valley of death. Unfortunately it’s a real trap for investors. A very high percentage of Biotech’ lose considerable value in the years after list whilst they travel thru the valley of death, costing early holders considerable money, because the punters lose patience and sell. Often leaving pissed off because of the endless cap raises at lower and lower share prices to fund the ongoing development. Then one day in less tha 10% of companies they see huge success and make massive money. Unfortunately for Steini he bought into both CHM and RAD far too early.

It the great news for IMU shareholders is that by November 2023 we will be on the other side of the valley of death and on our way to some serious big rewards. We got two amazing bits of news just this week., We cleared cohort 3 of the IT Monotherapy arm of the Vaxinia Mast Trial with the clear statement from our CEO that she is can’t wait to share the results with us. And secondly that we now own the front runner in the allergenic CD 19 CarT space. And it’s ready and FDA supported for Registrational Trials. IMU is fully funded to complete the development and Breakthrough Approvals phase of the first and only UNIVERSAL VACCINE AGAINST ALL CANCERS.

Just read that last sentence again. And think was all this worth a 6.5% dilution considering the massive uplift in valuation we got handed this week. It’s very important to spend time analysing the underlying value of the assets and IP that you Biotech Investment owns. Making decisions based on the out of control emotions some people get from watching the SP all day will end in tears for certain. Remember this is the hardest sector of the stock market to make successful investments, If you don’t have the money, experience and emotional resilience that’s required YOU WILL LOSE MONEY.. Stop blaming the Chairman for the mistakes YOU made.

Expand

Very well laid out and put together spill on what has actually taken place... Thanks for your spill TBULL!

I'm certainly excited for our next couple of announcements, which seem to be weekly at the minute, bring on the peer reviewed data set at SITC I say!

Go IMU

No.	Vol.	Price($)
6	1074997	5.1¢

No.

Vol.

Price($)

1074997

5.1¢

Price($)	Vol.	No.
5.2¢	1209633	6

Price($)

Vol.

No.

5.2¢

1209633

No.	Vol.	Price($)
3	549997	0.051
37	2917971	0.050
27	3229788	0.049
17	1256167	0.048
10	897463	0.047

No.

Vol.

Price($)

549997

0.051

2917971

0.050

3229788

0.049

1256167

0.048

897463

0.047

Price($)	Vol.	No.
0.052	707133	4
0.053	1043703	8
0.054	810794	4
0.055	1024326	11
0.056	633333	4

Price($)

Vol.

No.

0.052

707133

0.053

1043703

0.054

810794

0.055

1024326

0.056

633333

(20min delay)
Last 5.1¢		Change -0.002(3.77%)		Mkt cap ! $373.3M

Open	High	Low	Value	Volume
5.2¢	5.2¢	5.0¢	$669.7K	13.07M

Ann: Imugene Capital Raising Presentation, page-57

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Climate change to drive market trends to the moon

Fast-track assaying yields 182 g/t gold for iTech at new NT play

KGL sniffs 19% Cu from drilling at Rockface play in NT

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Imugene Capital Raising Presentation, page-57

Top Stories

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Climate change to drive market trends to the moon

Fast-track assaying yields 182 g/t gold for iTech at new NT play

KGL sniffs 19% Cu from drilling at Rockface play in NT

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News